|
1.
|
Brocker CN, Vasiliou V and Nebert DW:
Evolutionary divergence and functions of the ADAM and ADAMTS gene
families. Hum Genomics. 4:43–55. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
2.
|
White JM: ADAMs: modulators of cell-cell
and cell-matrix interactions. Curr Opin Cell Biol. 15:598–606.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
3.
|
Takeda S: Three-dimensional domain
architecture of the ADAM family proteinases. Semin Cell Dev Biol.
20:146–152. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4.
|
Liu H, Shim AH and He X: Structural
characterization of the ectodomain of a disintegrin and
metalloproteinase-22 (ADAM22), a neural adhesion receptor instead
of metalloproteinase: insights on ADAM function. J Biol Chem.
284:29077–29086. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5.
|
Janes PW, Saha N, Barton WA, et al: Adam
meets Eph: an ADAM substrate recognition module acts as a molecular
switch for ephrin cleavage in trans. Cell. 123:291–304. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
6.
|
Reiss K and Saftig P: The ‘a disintegrin
and metalloprotease’ (ADAM) family of sheddases: physiological and
cellular functions. Semin Cell Dev Biol. 20:126–137. 2009.
|
|
7.
|
Bax DV, Messent AJ, Tart J, et al:
Integrin alpha5beta1 and ADAM-17 interact in vitro and co-localize
in migrating HeLa cells. J Biol Chem. 279:22377–22386. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
8.
|
McGinn OJ, English WR, Roberts S, Ager A,
Newham P and Murphy G: Modulation of integrin alpha4beta1 by ADAM28
promotes lymphocyte adhesion and transendothelial migration. Cell
Biol Int. 35:1043–1053. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9.
|
Saha A, Backert S, Hammond CE, Gooz M and
Smolka AJ: Helicobacter pylori CagL activates ADAM17 to
induce repression of the gastric H, K-ATPase alpha subunit.
Gastroenterology. 139:239–248. 2010. View Article : Google Scholar
|
|
10.
|
Gooz P, Dang Y, Higashiyama S, Twal WO,
Haycraft CJ and Gooz M: A disintegrin and metalloenzyme (ADAM) 17
activation is regulated by alpha5beta1 integrin in kidney mesangial
cells. PLoS One. 7:e333502012. View Article : Google Scholar : PubMed/NCBI
|
|
11.
|
Milla ME, Leesnitzer MA, Moss ML, et al:
Specific sequence elements are required for the expression of
functional tumor necrosis factor-alpha-converting enzyme (TACE). J
Biol Chem. 274:30563–30570. 1999. View Article : Google Scholar
|
|
12.
|
Lorenzen I, Trad A and Grötzinger J:
Multimerisation of A disintegrin and metalloprotease protein-17
(ADAM17) is mediated by its EGF-like domain. Biochem Biophys Res
Commun. 415:330–336. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13.
|
Reddy P, Slack JL, Davis R, et al:
Functional analysis of the domain structure of tumor necrosis
factor-alpha converting enzyme. J Biol Chem. 275:14608–14614. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
14.
|
Tape CJ, Willems SH, Dombernowsky SL, et
al: Cross-domain inhibition of TACE ectodomain. Proc Natl Acad Sci
USA. 108:5578–5583. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15.
|
Lorenzen I, Lokau J, Düsterhöft S, et al:
The membrane-proximal domain of A Disintegrin and Metalloprotease
17 (ADAM17) is responsible for recognition of the interleukin-6
receptor and interleukin-1 receptor II. FEBS Lett. 586:1093–1100.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
16.
|
Smith KM, Gaultier A, Cousin H, Alfandari
D, White JM and DeSimone DW: The cysteine-rich domain regulates
ADAM protease function in vivo. J Cell Biol. 159:893–902. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
17.
|
Soond SM, Everson B, Riches DW and Murphy
G: ERK-mediated phosphorylation of Thr735 in TNFalpha-converting
enzyme and its potential role in TACE protein trafficking. J Cell
Sci. 118:2371–2380. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
18.
|
Edwards DR, Handsley MM and Pennington CJ:
The ADAM metalloproteinases. Mol Aspects Med. 29:258–289. 2008.
View Article : Google Scholar
|
|
19.
|
Kommaddi RP, Thomas R, Ceni C, Daigneault
K and Barker PA: Trk-dependent ADAM17 activation facilitates
neurotrophin survival signaling. FASEB J. 25:2061–2070. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
20.
|
McGowan PM, McKiernan E, Bolster F, et al:
ADAM-17 predicts adverse outcome in patients with breast cancer.
Ann Oncol. 19:1075–1081. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
21.
|
McGowan PM, Ryan BM, Hill AD, McDermott E,
O'Higgins N and Duffy MJ: ADAM-17 expression in breast cancer
correlates with variables of tumor progression. Clin Cancer Res.
13:2335–2343. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
22.
|
Tanaka Y, Miyamoto S, Suzuki SO, et al:
Clinical significance of heparin-binding epidermal growth
factor-like growth factor and a disintegrin and metalloprotease 17
expression in human ovarian cancer. Clin Cancer Res. 11:4783–4792.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
23.
|
Rosso O, Piazza T, Bongarzone I, et al:
The ALCAM shedding by the metalloprotease ADAM17/TACE is involved
in motility of ovarian carcinoma cells. Mol Cancer Res.
5:1246–1253. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
24.
|
Blanchot-Jossic F, Jarry A, Masson D, et
al: Up-regulated expression of ADAM17 in human colon carcinoma:
co-expression with EGFR in neoplastic and endothelial cells. J
Pathol. 207:156–163. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
25.
|
Dijkstra A, Postma DS, Noordhoek JA, et
al: Expression of ADAMs (‘a disintegrin and metalloprotease’) in
the human lung. Virchows Arch. 454:441–449. 2009.
|
|
26.
|
Badoual C, Bouchaud G, Agueznay Nel H, et
al: The soluble alpha chain of interleukin-15 receptor: a
proinflammatory molecule associated with tumor progression in head
and neck cancer. Cancer Res. 68:3907–3914. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
27.
|
Zheng X, Jiang F, Katakowski M, Zhang ZG,
Lu QE and Chopp M: ADAM17 promotes breast cancer cell malignant
phenotype through EGFR-PI3K-AKT activation. Cancer Biol Ther.
8:1045–1054. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
28.
|
Trad A, Hedemann N, Shomali M, Pawlak V,
Grotzinger J and Lorenzen I: Development of sandwich ELISA for
detection and quantification of human and murine a disintegrin and
metalloproteinase 17. J Immunol Methods. 371:91–96. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
29.
|
Trad A, Hansen HP, Shomali M, et al:
ADAM17-overexpressing breast cancer cells selectively targeted by
antibody-toxin conjugates. Cancer Immunol Immunother. Sep 1–2012,
(Epub ahead of print).
|
|
30.
|
Yamamoto K, Trad A, Baumgart A, et al: A
novel bispecific single-chain antibody for ADAM17 and CD3 induces
T-cell-mediated lysis of prostate cancer cells. Biochem J.
445:135–144. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
31.
|
Zigrino P, Nischt R and Mauch C: The
disintegrin-like and cysteine-rich domains of ADAM-9 mediate
interactions between melanoma cells and fibroblasts. J Biol Chem.
286:6801–6807. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
32.
|
Chalaris A, Rabe B, Paliga K, et al:
Apoptosis is a natural stimulus of IL6R shedding and contributes to
the proinflammatory trans-signaling function of neutrophils. Blood.
110:1748–1755. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
33.
|
Jovic M, Naslavsky N, Rapaport D, Horowitz
M and Caplan S: EHD1 regulates beta1 integrin endosomal transport:
effects on focal adhesions, cell spreading and migration. J Cell
Sci. 120:802–814. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
34.
|
Chalaris A, Adam N, Sina C, et al:
Critical role of the disintegrin metalloprotease ADAM17 for
intestinal inflammation and regeneration in mice. J Exp Med.
207:1617–1624. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
35.
|
Baumgart A, Seidl S, Vlachou P, et al:
ADAM17 regulates epidermal growth factor receptor expression
through the activation of Notch1 in non-small cell lung cancer.
Cancer Res. 70:5368–5378. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
36.
|
Sternlicht MD and Sunnarborg SW: The
ADAM17-amphiregulin-EGFR axis in mammary development and cancer. J
Mammary Gland Biol Neoplasia. 13:181–194. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
37.
|
Kuramochi H, Nakajima G, Kaneko Y, et al:
Amphiregulin and Epiregulin mRNA expression in primary colorectal
cancer and corresponding liver metastases. BMC Cancer. 12:882012.
View Article : Google Scholar : PubMed/NCBI
|
|
38.
|
Toquet C, Colson A, Jarry A, et al: ADAM15
to alpha5beta1 integrin switch in colon carcinoma cells: A late
event in cancer progression associated with tumor dedifferentiation
and poor prognosis. Int J Cancer. 130:278–287. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
39.
|
Lucas N and Day ML: The role of the
disintegrin metalloproteinase ADAM15 in prostate cancer
progression. J Cell Biochem. 106:967–974. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
40.
|
Desiderio UV, Zhu X and Evans JP: ADAM2
interactions with mouse eggs and cell lines expressing
alpha4/alpha9 (ITGA4/ITGA9) integrins: implications for
integrin-based adhesion and fertilization. PLoS One. 5:e137442010.
View Article : Google Scholar : PubMed/NCBI
|
|
41.
|
Kornfeld JW, Meder S, Wohlberg M, et al:
Overexpression of TACE and TIMP3 mRNA in head and neck cancer:
association with tumour development and progression. Br J Cancer.
104:138–145. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
42.
|
Gooz M: ADAM-17: the enzyme that does it
all. Crit Rev Biochem Mol Biol. 45:146–169. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
43.
|
Zheng X, Jiang F, Katakowski M, Lu Y and
Chopp M: ADAM17 promotes glioma cell malignant phenotype. Mol
Carcinog. 51:150–164. 2012. View Article : Google Scholar : PubMed/NCBI
|
